Jasper Therapeutics received a notice from Nasdaq on August 21, 2026, indicating it no longer meets the minimum stockholders' equity requirement of $2.5 million for continued listing under Listing Rule 5550(b)(1). The company has until October 5, 2026, to submit a compliance plan and anticipates regaining compliance through stockholder approval of converting its Non-Voting Convertible Preferred Stock at an upcoming special meeting. Failure to regain compliance could lead to delisting proceedings before Nasdaq's Hearing Panel. Jasper Therapeutics operates in the biotechnology industry, focusing on developing therapies for rare diseases.

Jasper Therapeutics reported second quarter 2026 financial results and provided a corporate update. The company completed the acquisition of Kira Pharmaceuticals in July 2026 via an all-stock transaction, creating a combined entity with a robust portfolio for immune-mediated diseases. Concurrently, Jasper raised $132 million in gross proceeds through a private placement of non-voting convertible preferred stock. As of June 30, 2026, the company held $7.3 million in cash and reported a net loss of $2.8 million, or $0.10 per share. The combined company plans to advance lead asset KP-104, progress briquilimab toward a potential BLA, and commence first-in-human studies for KP-701. Jasper Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapies for immune-mediated diseases.